论文部分内容阅读
目的:检测肾移植受者尿液中单核细胞趋化性肽-1(MCP-1)的含量,了解其变化规律,探讨其在肾移植急性排斥反应中的意义。方法:用ABC-ELISA法,检测尿液中MCP-1的含量。结果:肾功能稳定的肾移植受者尿液中MCP-1的水平为(416±21)μg/L,对照组为(408±11)μg/L,两者无明显差 别。发生急性排斥反应的肾移植受者,尿液中MCP-1的水平为(1195±58)μg/L,明显高于对照组和肾功能稳定者(P<0.01)。经抗排斥治疗后,对治疗有反应的急性排斥反应受者,尿液中MCP-1的水平明显下降。结论:尿液中MCP-1的水平与肾移植急性排斥反应有密切关系。检测尿液中MCP-1的水平有助于急性排斥反应的诊断及预后判断。
OBJECTIVE: To detect the level of monocyte chemoattractant peptide-1 (MCP-1) in the urine of renal allograft recipients, and to investigate the changes of monocyte chemoattractant peptide-1 (MCP-1) in renal transplant recipients and its significance in acute rejection after renal transplantation. Methods: ABC-ELISA method was used to detect the content of MCP-1 in urine. Results: The level of MCP-1 in the urine of patients with stable renal function was (416 ± 21) μg / L and that of the control group (408 ± 11) μg / L respectively. There was no significant difference between the two groups. In acute renal transplant recipients, the level of MCP-1 in urine was (1195 ± 58) μg / L, which was significantly higher than that in control group and stable renal function (P <0.01). After anti-rejection therapy, recipients of acute rejection who respond to treatment have significantly decreased MCP-1 levels in their urine. Conclusion: The level of MCP-1 in urine is closely related to the acute rejection of kidney transplantation. Testing the level of MCP-1 in urine is helpful for the diagnosis and prognosis of acute rejection.